Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, July 26, 2023
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
[ Wed, Jul 26th 2023
] - WOPRAI
Peter Lawson Maintained (SNDX) at Buy with Increased Target to $34 on, Jul 26th, 2023
Peter Lawson of Barclays, Maintained "Syndax Pharmaceuticals, Inc." (SNDX) at Buy with Increased Target from $31 to $34 on, Jul 26th, 2023.
Peter has made no other calls on SNDX in the last 4 months.
There are 4 other peers that have a rating on SNDX. Out of the 4 peers that are also analyzing SNDX, 0 agree with Peter's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Peter
- Kalpit Patel of "B. Riley Securities" Maintained at Strong Buy with Increased Target to $36 on, Tuesday, July 25th, 2023
- Michael Schmidt of "Guggenheim" Maintained at Strong Buy with Increased Target to $42 on, Tuesday, July 25th, 2023
- Edward White of "HC Wainwright & Co." Reiterated at Strong Buy with Increased Target to $38 on, Monday, July 24th, 2023
- Justin Zelin of "BTIG" Maintained at Strong Buy with Increased Target to $35 on, Monday, June 26th, 2023
